Table 4.
Comparison Risk Factors Associated with Severe Adverse Events
| Variables | Severe adverse events (N= 115) |
Without severe adverse events (N= 448) |
P-value |
|---|---|---|---|
| Type of malignancy, (n, %) | |||
| Acute lymphoblastic leukemia, High risk | 33 (28.7) | 119 (26.6) | 0.639 |
| Acute lymphoblastic leukemia, Standard risk | 8 (7) | 65 (14.5) | 0.03 |
| Acute myeloid leukemia | 40 (34.8) | 100 (22.3) | 0.008 |
| High risk group, (n, %) | 105 (91.0) | 321 (71.0) | <0.001 |
| Chemotherapy-induction for leukemia, (n, %) | 22 (40) | 53 (25) | 0.042 |
| Treatment not according to CPG, (n, %) | 54 (47) | 134 (29.9) | 0.01 |
| Previous history of febrile neutropenia, (n, %) | 63 (49.4) | 274 (61.2) | 0.492 |
| G-CSF use, (n, %) | 35 (30.4) | 129 (28.8) | 0.731 |
| Steroids use, (n, %) | 53 (46.1) | 173 (38.6) | 0.166 |
| Central venous catheter insertion, (n, %) | 83 (72.2) | 143 (31.9) | <0.001 |
| Antifungal use in past 6 months, (n, %) | 29 (25.2) | 94 (21.0) | 0.376 |
| Type of pathogen, (n, %) | |||
| Bacteria | 43 (37.3) | 111 (24.7) | 0.009 |
| Virus | 11 (9.5) | 21 (4.7) | 0.067 |
| Fungus | 17 (14.7) | 10 (2.2) | <0.001 |
G-CSF, Granulocyte colony stimulating factor; CPG, clinical practice guideline; Mann-Whitney Test and Fisher's exact test